Unlocking Heart Failure's Secret Weapon: The Transformative Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Heart Failure with Reduced Ejection Fraction

Abstract

Heart failure (HF) with reduced ejection fraction (EF) affects nearly half of HF patients and is associated with high mortality and morbidity rates, particularly among the elderly. Severe exercise intolerance is a primary chronic symptom in HF patients with reduced EF (HFrEF), significantly impairing their quality of life. Therefore, enhancing exercise capacity and overall quality of life remains a critical clinical objective for managing HFrEF. Recent randomized controlled trials (RCTs) and meta-analyses have demonstrated the cardiovascular benefits of sodium–glucose cotransporter 2 (SGLT-2) inhibitors in HFrEF patients. Despite multiple RCTs investigating SGLT-2 inhibitors in this population, results have shown inconsistency, partly attributed to limited statistical power. Further exploration of the mechanisms underlying the cardiovascular improvements associated with SGLT2 inhibitors in patients with HFrEF is warranted. This abstract underscores the importance of investigating the therapeutic potential of SGLT2 inhibitors in improving cardiovascular outcomes among HFrEF patients, thereby offering new insights for optimal management strategies.